clofazimine inhalational (MNKD-101) / MannKind 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
clofazimine inhalational (MNKD-101) / MannKind
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
ACTRN12621001702808p: A Study of Clofazimine Inhalation Suspension (MNKD-101) in Healthy Volunteers

Not yet recruiting
1
40
 
MannKind Corporation, MannKind Corporation
Pulmonary Nontuberculous Mycobacteria Infections
 
 
ACTRN12621001702808: A Study of Clofazimine Inhalation Suspension (MNKD-101) in Healthy Volunteers

Completed
1
40
 
MannKind Corporation, MannKind Corporation
Pulmonary Nontuberculous Mycobacteria Infections
 
 

Download Options